Abstract: A deep and repetitive transcranial magnetic stimulation of an individual is performed by applying magnetic pulses at least to a region of the scalp of the individual, the region being at least the bilateral prefrontal cortex, and can include preferably the bilateral prefrontal cortex and can include the insula. A threshold intensity of the magnetic pulses is determined by applying to the individual one or more reference magnetic stimulations, and a reaction of the individual to the reference stimulation is determined. The reaction corresponds to a right thumb movement. A magnetic stimulation is repeatedly applied for at least 80 trains per session for a duration not exceeding 2 seconds each with a time interval between a train application and the next one not less than 20 seconds, wherein the magnetic stimulation has a frequency of at least 18 Hz with an intensity of stimulation at least 120% of the threshold intensity.

Abstract: Method for a deep and repetitive transcranial magnetic stimulation of an individual by means of magnetic pulses applied at least to a region of the scalp of the individual, said region being at least the bilateral prefrontal cortex, preferably the bilateral prefrontal cortex and the insula, the method comprising the steps of determining a threshold intensity of said magnetic pulses by applying to the individual one or more reference magnetic stimulations and determining a reaction of the individual to said reference stimulation, wherein said reaction corresponds to a right thumb movement and repeatedly applying a magnetic stimulation for at least 80 trains per session for a duration not exceeding 2 seconds each with a time interval between a train application and the next one not less than 20 seconds, wherein said magnetic stimulation has a frequency of at least 18 Hz with an intensity of stimulation at least 120% of the threshold intensity.

Abstract: The inventors have made the surprising discovery that when ceramide production is upregulated in the infarct and at-risk areas upon reperfusion injury in the heart, such upregulation is effected through the de novo ceramide synthesis pathway. Upon treatment of cardiac tissues subject to reperfusion injury with a specific inhibitor of the novo ceramide synthesis pathway (myriocin), the inventors have determined that the inhibition of such pathway not only reduces the inflammation of the interested area, but most surprisingly reduces infarct size, ameliorates cardiac contractility and activates cell detoxification and survival programs. There is thus provided an inhibitor of de novo ceramide synthesis pathway, particularly myriocin, for the treatment of cardiac reperfusion injury.